WO2000060355A3 - Lfa-1 regulatory binding site and uses thereof - Google Patents

Lfa-1 regulatory binding site and uses thereof Download PDF

Info

Publication number
WO2000060355A3
WO2000060355A3 PCT/US2000/008841 US0008841W WO0060355A3 WO 2000060355 A3 WO2000060355 A3 WO 2000060355A3 US 0008841 W US0008841 W US 0008841W WO 0060355 A3 WO0060355 A3 WO 0060355A3
Authority
WO
WIPO (PCT)
Prior art keywords
lfa
binding site
regulatory binding
regulatory
binding
Prior art date
Application number
PCT/US2000/008841
Other languages
French (fr)
Other versions
WO2000060355A2 (en
Inventor
Donald Staunton
Der Vieren Monica Van
Jeff Huth
Kerry Fowler
Mark Orme
Edward T Olejniczak
Original Assignee
Icos Corp
Abbott Lab
Donald Staunton
Vieren Monica V D
Jeff Huth
Kerry Fowler
Mark Orme
Edward T Olejniczak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp, Abbott Lab, Donald Staunton, Vieren Monica V D, Jeff Huth, Kerry Fowler, Mark Orme, Edward T Olejniczak filed Critical Icos Corp
Priority to EP00921627A priority Critical patent/EP1175615A2/en
Priority to AU41920/00A priority patent/AU4192000A/en
Publication of WO2000060355A2 publication Critical patent/WO2000060355A2/en
Publication of WO2000060355A3 publication Critical patent/WO2000060355A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods to negatively regulate LFA-1 binding to an ICAM that binds LFA-1 are provided, in addition to a novel regulatory binding site on LFA-1.
PCT/US2000/008841 1999-04-02 2000-04-03 Lfa-1 regulatory binding site and uses thereof WO2000060355A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00921627A EP1175615A2 (en) 1999-04-02 2000-04-03 Lfa-1 regulatory binding site and uses thereof
AU41920/00A AU4192000A (en) 1999-04-02 2000-04-03 Lfa-1 regulatory binding site and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547799A 1999-04-02 1999-04-02
US09/285,477 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000060355A2 WO2000060355A2 (en) 2000-10-12
WO2000060355A3 true WO2000060355A3 (en) 2001-02-08

Family

ID=23094406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008841 WO2000060355A2 (en) 1999-04-02 2000-04-03 Lfa-1 regulatory binding site and uses thereof

Country Status (3)

Country Link
EP (1) EP1175615A2 (en)
AU (1) AU4192000A (en)
WO (1) WO2000060355A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414461A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US7323552B2 (en) 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
JP2004504827A (en) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション High affinity integrin polypeptides and methods of use
AU2003267991B2 (en) 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
US9945873B2 (en) * 2011-01-21 2018-04-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
WO2015017354A1 (en) * 2013-07-29 2015-02-05 University Of Houston System Volatile organic gases as bioindicators for transplant rejection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010652A1 (en) * 1989-03-09 1990-09-20 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
WO1995025173A1 (en) * 1994-03-14 1995-09-21 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
WO1996024063A1 (en) * 1995-01-30 1996-08-08 The General Hospital Corporation Methods for identifying integrin antagonists
WO2000039081A2 (en) * 1998-12-29 2000-07-06 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010652A1 (en) * 1989-03-09 1990-09-20 Dana Farber Cancer Institute Method of treating viral infections using lfa-1
WO1995025173A1 (en) * 1994-03-14 1995-09-21 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
WO1996024063A1 (en) * 1995-01-30 1996-08-08 The General Hospital Corporation Methods for identifying integrin antagonists
WO2000039081A2 (en) * 1998-12-29 2000-07-06 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUTH, J. ET AL.: "NMR and mutagenisis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 97, 9 May 2000 (2000-05-09), pages 5231 - 5236, XP000938664 *
SAWYER, J. SCOTT ET AL: "Synthetic and Structure/Activity Studies on Acid-Substituted 2-Arylphenols: Discovery of 2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)- hydroxyphenoxy]- propoxy]phenoxy]benzoic Acid, a High-Affinity Leukotrien B4 Receptor Antagonist", J. MED. CHEM. (1995), 38(22), 4411-32, XP000939042 *

Also Published As

Publication number Publication date
EP1175615A2 (en) 2002-01-30
WO2000060355A2 (en) 2000-10-12
AU4192000A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
AU5782900A (en) Secure, limited-access database system and method
ZA200000079B (en) Driver, fastener and forming tool.
AU2001268752A1 (en) Sales tax assessment, remittance and collection system
AU2003210576A1 (en) A user authentication system and methods thereof cross reference to related applications.
AU2003304567A1 (en) Intelligent deception verification system
AU2002230974A1 (en) Day trading system
GB9811082D0 (en) Improvements in phase-separation etc.members
AU7492500A (en) Protective topical composition, products including the same, and methods
AU2001290141A1 (en) Variable automated response system
AU1887900A (en) Marked, difficult-to-counterfeit documents
AU4430199A (en) Tankyrase, a trfi binding protein
MXPA01009915A (en) INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF.
WO2001098367A3 (en) Neuroactive peptides for treatment of hypoxia and related conditions
WO2000060355A3 (en) Lfa-1 regulatory binding site and uses thereof
AU2001272989A1 (en) Composting system
AU2467099A (en) A spreading, crushing or cutting device
AU2001276425A1 (en) Machine for planting stakes, poles or the like
AU2094401A (en) Automated bindery log extension
AU2002306326A1 (en) General-purpose autentication system in organization
AU7683998A (en) Enzyme derived from thermophilic organisms that functions as a chromosomal replicase, and preparation and uses thereof
WO2002035297A3 (en) System for controlling operational sequences
HK1035961A1 (en) A septum for battery and the battery using the same.
EP1037534A4 (en) A fagopyrum cymosum (trev.) meisn composition, method to prepare and analyze the same and uses thereof
AU3359501A (en) Fertilizer, ion exchanger and method for the production thereof
AU2002214198A1 (en) Sealing, trimming and finishing strips

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000921627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000921627

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000921627

Country of ref document: EP